It is noteworthy that glucocorticoids have recently been confirmed to induce skeletal muscle atrophy through the NLRP3/caspase-1/GSDMD pathway (194, 195), and glucocorticoids are the first choice in the treatment of patients with DM. This evidence concerns the gene NLRP3 and dermatomyositis.